Raphael Pharmaceutical details routine board change

Raphael Pharmaceutical Inc. reported a change in its Board of Directors.

Accepted by SEC EDGAR 03/24/2026 - 04:01 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Raphael Pharmaceutical Inc. reported a change in its Board of Directors. On December 31, 2025, the term of service of Dr. Yehuda Eliya as a board member expired, and he ceased to serve as a director as of that date. The company states that Dr. Eliya’s departure was not related to any disagreement with the company regarding its operations, policies, or practices, indicating a routine end-of-term transition rather than a conflict-driven resignation.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did Raphael Pharmaceutical Inc. (RAPH) disclose?

Raphael Pharmaceutical Inc. disclosed that Dr. Yehuda Eliya’s term on the Board of Directors expired on December 31, 2025, and he ceased serving as a director effective that date, reflecting a scheduled end of service rather than an abrupt departure.

Was Dr. Yehuda Eliya’s departure from RAPH’s board due to a disagreement?

No. The company states that Dr. Yehuda Eliya’s departure from the board was not related to any disagreement with the company on its operations, policies, or practices, suggesting a routine governance transition instead of a dispute-driven resignation.

On what date did Dr. Yehuda Eliya stop serving as a director of RAPH?

Dr. Yehuda Eliya ceased serving as a director of Raphael Pharmaceutical Inc. effective December 31, 2025. His term on the Board of Directors expired on that date, marking the official end of his board service with the company.

Which Raphael Pharmaceutical Inc. executive signed the 8-K about the board change?

The 8-K reporting the board change was signed by Shlomo Pilo, Chief Executive Officer of Raphael Pharmaceutical Inc. His signature indicates the report was authorized and submitted on behalf of the registrant under Exchange Act requirements.

Where is Raphael Pharmaceutical Inc. headquartered according to this filing?

Raphael Pharmaceutical Inc. lists its principal executive offices at 4 Lui Paster, Tel Aviv-Jaffa, Israel, 6803605, with a contact telephone number of +972 52 775 5072, indicating the company’s main operational location in Israel.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001415397 0001415397 2025-12-31 2025-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 24, 2026 (December 31, 2025)

RAPHAEL PHARMACEUTICAL INC.

(Exact Name of Registrant as Specified in Its Charter)

Nevada		000-53002		26-0204284
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

4 Lui Paster Tel Aviv-Jaffa, Israel		6803605
(Address of Principal Executive Offices)		(Zip Code)

+972 52 775 5072

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.

On December 31, 2025, the term of service of Dr. Yehuda Eliya as a member of the Board of Directors (the “Board”) of the Company expired, and he ceased to serve as a director of the Company effective as of such date.

Dr. Eliya’s departure from the Board was not the related to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	RAPHAEL PHARMACEUTICAL INC.
	By:	/s/ Shlomo Pilo
	Name:	Shlomo Pilo
	Title:	Chief Executive Officer

Date: March 24, 2026

2

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.9 KB